Symposium (ID: SYMP01) Innovative treatment approaches of inherited neuromuscular disorders Saturday, 23 May 2020 10:00:00 AM - 12:00:00 PM Main Auditorium Chairpersons: Maria Judit Molnar, Budapest, Hungary (ID: 62173) Teresinha Evangelista, Paris France Gene therapeutic approaches of neuromuscular disorders (ID: SYMP01_1) Teresinha Evangelista, Paris, France (ID: 34168) The evolving landscape of RNA-based therapies (ID: SYMP01_2) Giuseppe Vita, Messina, Italy (ID: 15217) Towards a better understanding of enzyme replacement therapies (ID: SYMP01_3) Mark Roberts, Manchester, United Kingdom (ID: 16842) The role of small molecule approaches treating inherited neuromuscular disorders (ID: SYMP01_4) Maria Judit Molnar, Budapest, Hungary (ID: 62173) Scientific/Educational Content: Recent advances in understanding pathophysiological and genetic mechanisms of some neuromuscular diseases and a rapid progress in new pharmacological technologies led to an accelerated development of innovative treatments, generating an unexpected therapeutic revolution. The symposia will focus on already commercially available drugs, just approved drugs and new therapeutic promises in the treatment of inherited neuromuscular disorders. The lectures will cover the topics of gene therapy, RNA based treatments, enzyme replacement therapies and innovative small molecule approaches (new chemical entities and repositioned drugs) as well. (ID: SYMP02) EAN/MDS-ES: Movement disorders in the emergency room Saturday, 23 May 2020 10:00:00 AM - 12:00:00 PM Room Oslo Chairpersons: Timothy Lynch, Dublin, Ireland (ID: 7109) Movement disorders in congenital and acquired metabolic diseases (ID: SYMP02_1) Miryam Carecchio, Padua, Italy (ID: 44445) How to recognize an acute functional movement disorder (ID: SYMP02_2) Jon Stone, Edinburgh, United Kingdom Movement disorders in autoimmune encephalitides (ID: SYMP02_3) Maria Stamelou, Athens, Greece (ID: 28934) Drug-induced movement disorders (ID: SYMP02_4) Timothy Lynch, Dublin, Ireland (ID: 7109) Scientific/Educational Content: Patients presenting with acute or subacute movement disorders are frequently encountered in routine clinical practice. The number of possible causes of an acute movement disorders is wide, and neurologists must be able to rapidly perform a case-based differential diagnosis.
25
Embed
Symposium - ean.org...This symposium will address the most frequent causes of movement disorders with an acute presentation including treatable conditions not to miss. (ID: SYMP03)
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Symposium (ID: SYMP01) Innovative treatment approaches of inherited neuromuscular disorders
Saturday, 23 May 2020
10:00:00 AM - 12:00:00 PM
Main Auditorium
Chairpersons: Maria Judit Molnar, Budapest, Hungary (ID: 62173)
Teresinha Evangelista, Paris France
Gene therapeutic approaches of neuromuscular disorders (ID: SYMP01_1)
Teresinha Evangelista, Paris, France (ID: 34168)
The evolving landscape of RNA-based therapies (ID: SYMP01_2)
Giuseppe Vita, Messina, Italy (ID: 15217)
Towards a better understanding of enzyme replacement therapies (ID: SYMP01_3)
Mark Roberts, Manchester, United Kingdom (ID: 16842)
The role of small molecule approaches treating inherited neuromuscular disorders (ID:
SYMP01_4)
Maria Judit Molnar, Budapest, Hungary (ID: 62173)
Scientific/Educational Content:
Recent advances in understanding pathophysiological and genetic mechanisms of some
neuromuscular diseases and a rapid progress in new pharmacological technologies led to an
accelerated development of innovative treatments, generating an unexpected therapeutic revolution.
The symposia will focus on already commercially available drugs, just approved drugs and new
therapeutic promises in the treatment of inherited neuromuscular disorders. The lectures will cover
the topics of gene therapy, RNA based treatments, enzyme replacement therapies and innovative
small molecule approaches (new chemical entities and repositioned drugs) as well.
(ID: SYMP02) EAN/MDS-ES: Movement disorders in the emergency room
Neurological complications of Checkpoint Inhibitors (ID: FW19_1)
Andreas Hottinger, Lausanne, Switzerland (ID: 72694)
Neurological complications of Car-T-cell therapy (ID: FW19_2)
Antoine Carpentier, Paris, France (ID: 7035)
Neurological complications of targeted therapies and radiosurgery (ID: FW19_3)
Roberta Rudà, Turin, Italy
Scientific Content:
The audience will be updated on recent advances regarding molecular factors of prognostic/predictive
importance in gliomas and neurofibromatosis, mechanisms of repair of damage to the brain tissue
from antitumor treatments and strategies to minimize neurotoxicity
(ID: FW20) Fitness to drive in neurological disorders Monday, 25 May 2020
8:00:00 AM - 9:30:00 AM
Room Paris
Chairpersons: David Schreier, Bern, Switzerland (ID: 67199)
Fitness to drive in sleepy patients (ID: FW20_1)
David Schreier, Bern, Switzerland (ID: 67199)
Fitness to drive in patients with cognitive impairments (ID: FW20_2)
Dorota Religa, Stockholm, Sweden (ID: 23643)
Fitness to drive in patients with epilepsy (ID: FW20_3)
Philip Smith, Cardiff, United Kingdom (ID: 92536)
Scientific Content:
In this Focused Workshop, we would like to inform regarding the latest research and their impact on
the judgement of fitness to drive. Due to many reasons, being able to drive is very important for
patients. However, the judgment of fitness to drive often remains challenging. The number of patients
with neurological disorders is increasing, while the opportunities for treatment and the availability and
quality of driving assistant systems are improving, enabling more severely disabled patients to carry
on driving. Therefore, not only the number but also complexity of decisions that need to be made by
physicians, particularly neurologists, has increased.
(ID: FW21) Clinical impact of white matter hyperintensities and microbleeds Sunday, 24 May 2020
8:00:00 AM - 9:30:00 AM
Room Copenhagen
Chairpersons: Stephanie Debette, Bordeaux, France (ID: 46210)
David Werring, London, United Kingdom (ID: 16495)
New molecular insights into cerebral small vessel disease (ID: FW21_1)
Martin Dichgans, Munich, Germany (ID: )
Epidemiology and genomics of cerebral small vessel disease: implications for treatment (ID:
FW21_2)
Stephanie Debette, Bordeaux, France (ID: 46210)
Diagnostic and therapeutic importance of microbleeds (ID: FW21_3)
David Werring, London, United Kingdom (ID: 16495)
Scientific Content:
Within the aging population the number of patients showing MRI abnormalities, in particular white
matter hyperintensities (WMH) and microbleeds increases. This workshop provides novel insights into
cerebral small vessel disease underlying WMH and their implication for treatment. A further important
clinical problem covered relates to balancing the risk of future intracranial bleeding compared to the
risk of recurrent ischemic stroke in patients with a high burden of microbleeds.
Special Session SPS13: COVID-19 Session EAN 2020
Sunday, 24 May 2020
15:00:00 AM - 16:30:00 PM
Main Auditorium
Chairpersons: Elena Moro
Tom Jenkins,
1. Ethical considerations during the COVID-19 Pandemic
2. Diagnosis and medical care of COVID-19
3. Neurological manifestations and outcome of SARS-CoV-2 infection
4. Virological and neurobiological view on SARS-CoV-2
Renaud Du Pasquier, Lausanne, Switzerland
(ID: SpS01) WHO Strategies in brain diseases: noncommunicable diseases and universal
healthcare coverage
Saturday, 23 May 2020
8:00:00 AM - 9:30:00 AM
Room Seville
Chairpersons: William Carroll (WFN President)
Günther Deuschl, Kiel, Germany
Global, regional, and national burden of neurological disorders
Ettore Beghi, Italy
Stroke and dementia burden- opportunities for prevention
David Tanne, Haifa, Israel
Strategic Epilepsy Initiatives in the WHO
Alla Guekht, Moscow, Russia
4a) Migraine and tension-type headache in Europe- reducing the burden of disease
Timothy Steiner, London, United Kingdom
4b) WHO strategies in promoting brain health
WHO Representative (TBC)
Scientific Content:
As demonstrated by GBD study, the burden of neurological disorders, as measured by the absolute
number of DALYs, continues to increase. As populations are growing and ageing, the prevalence of
major disabling neurological disorders has been predicted to increase further.
Stroke remains one of the leading causes of death and disability in Europe. Stroke is more prevalent in the elderly, however, stroke in the young and middle-aged adults are increasingly frequent, likely because of metabolic risk factors, including obesity and diabetes mellitus. Recent advances in stroke treatment allowed to prevent severe disability and mortality is huge number of patients worldwide,
and there is a compelling evidence that stroke is highly preventable, treatable and manageable, and the potential exists to drastically reduce the burden of stroke and its long-term consequences. The medical rationale for stroke being a disease of the brain is overwhelming, and in the ICD-11 stroke will be appropriately placed in the section of diseases of the nervous system. Epilepsy is a chronic noncommunicable disease of the brain that affects people. Around 50 million people of all ages worldwide have epilepsy, making it one of the most common neurological diseases globally. Nearly 80% of people with epilepsy live in low- and middle-income countries. It is estimated that up to 70% of people living with epilepsy could live seizure- free if properly diagnosed and treated. The risk of premature death in people with epilepsy is up to three times higher than for the general population. There is a growing evidence that a substantial proportion of epilepsies in brain diseases is preventable. The methods of seizure prediction are being developed. In 2019 the first-ever Global Report on epilepsy had been published by the WHO, ILAE and IBE. The WHO is paying increasing attention to the burden of the preventable noncommunicable diseases (NCDs), including brain diseases, in the close collaboration with the WFN and other leading neurological organizations. Advancing toward providing universal access to comprehensive, quality, progressively expanded health services, should take into account the health needs of people, including those affected by brain diseases and other NCDs.
(ID: SpS02) Acute Neurology
Saturday, 23 May 2020
3:00:00 PM - 4:30:00 PM
Room Budapest
Chairpersons: Simon Jung, Bern, Switzerland (ID: 47914)
Pitfalls in the management of neurological emergencies (ID: SPS02_1)
Simon Jung, Bern, Switzerland (ID: 47914)
Pitfalls in the management of patients on the neuro ICU (ID: SPS02_2)
Robin Howard, London, United Kingdom (ID: ??)
Outcome prediction in patients with hypoxic encephalopathy (ID: SPS02_3)
C. David Marsden Lecture: The impunity of the Basal Ganglia to interventional therapies in
Parkinson's disease - An advantageous mystery (ID: SPS03_1)
José Obeso, Madrid, Spain (ID: 24657)
Video Cases (ID: SPS03_2)
Carlo Colosimo, Italy
Cristian Falup-Pecurariu, Romania
(ID: SPS04) The care of Rare Neurological Diseases, 2020
Saturday, 23 May 2020
4:45:00 PM - 6:15:00 PM
Room Budapest
Chairpersons: Antonio Federico, Siena, Italy
Marianne de Visser, Amsterdam, The Netherlands
Introduction: the need of care and the possibility to give it
Antonio Federico, Siena, Italy
New genetic therapies: for which diseases and for which patients?
Jean Marc Burgunder, Bern, Switzerland
Health or hope? The cost and availability of new orphan therapies in Europe.
Maria Judit Molar, Budapest, Hungary
Neurorehabilitation for Rare Diseases. From theory to practice
Dafin Muresanu, Romania
Conclusions
Marianne de Visser, Amsterdam, The Netherlands
Scientific Content:
The general care of rare neurologic diseases in Europe will be discussed, including its sustainability, the
cost-benefit ratio, the hope of the families, the scientific data on new gene therapies, and the
important role of neurorehabilitation. The audience will be provided with a global review on the
different care approaches to these often-neglected group of disorders, and one group of rare diseases
will be dealt with in-depth.
(ID: SPS05) New neurological guidelines
Sunday, 24 May 2020
8:00:00 AM - 9:30:00 AM
Main Auditorium
Chairpersons: Maurizio Leone, Italy
Marie Vidailhet
EAN guideline on the diagnosis of coma and other disorders of consciousness (ID: SPS05_1)
Daniel Kondziella (ID: )
EAN consensus for developing and reporting guidelines for rare neurological diseases(ID:
SPS05_2)
Katina Aleksovska
Monogenic cerebral small vessel diseases: diagnosis and therapy. Consensus
recommendations of EAN (ID: SPS05_3)
Hugh Markus
EAN guideline on the management of narcolepsy (update) (ID: SPS05_4)
Ulf Kallweit
Scientific Content:
This special session is the yearly appointment for presenting the most relevant guidelines produced by
EAN during the past year. EAN guidelines are currently suggested and prepared by ad-hoc Task Forces,
usually appointed by the Scientific Panels, according to a well-established procedure, requiring a first
proposal, and a protocol. Since 2019, 3 new guidelines were published in European Journal of
Neurology, 5 are submitted, 16 are ongoing, and 2 are at the protocol stage. Six further proposals have
been recently accepted. The EAN Guideline Production Group is in charge of controlling the guideline
production process and helping with methodological assistance, and has recently updated the
procedure, available in EANpages.
During the last two years concerns have been raised by the Task Forces, especially related the
methodology to be used in contexts lacking evidence, such as rare diseases. To enhance and improve
the development and reporting of guidelines for rare neurological diseases, EAN has appointed a task
force with the aim to produce a specific guidance through a Delphi consensus. The results of this expert
consensus will be presented in this session.
The other three guidelines are all dealing with disorders where evidence is lacking. A joint effort of the
Stroke and Neurogenetics Panels led to an expert consensus for the management of the most common
monogenic causes of juvenile stroke, including CADASIL, CARASIL, MELAS, and others. Recognition of
the genetic disorders causing stroke is important for a correct diagnosis, for genetic counselling and,
where available, for a correct therapeutic management.
A guideline on management of narcolepsy, a condition affecting approximately 1 out of 2000 persons
in Europe, has been produced by a task force of neurologists and sleep experts appointed by EAN in
agreement with the European Sleep Research Society and the European Narcolepsy Network.
Last, although acknowledging limited evidence to support diagnostic decisions in coma and other
disorders of consciousness, the EAN Panel Coma and Disorders of Consciousness has produced a
guideline to provide the state-of-the-art evidence in this field, summarizing data from bedside
examination techniques, functional neuroimaging and electroencephalography.
During this session, guideline papers on neurological management that were recently published in the
European Journal of Neurology by EAN and partner societies, will be introduced. If you wish to receive
more information on EAN guideline production, you are welcome to visit the EAN booth "Research".
(ID: SpS07) Resident and Research Fellow Section - Unleash your potential with EAN!
Sunday, 24 May 2020
4:45:00 PM - 6:15:00 PM
CbW Room
Chairpersons: Giovanni Di Liberto, Geneva, Switzerland (ID: 69196)
Successful stories from EAN Clinical Fellowship recipients (ID: SPS07_1)
Alberto Vogrig, Udine, Italy (ID: 44344)
Successful stories from EAN Research Fellowship recipients (ID: SPS07_2)
Bettina Balint, London, United Kingdom (ID: 49883)
TBA (ID: SPS07_3)
Ana Felipa De Freitas Ladeira, Lisbon, Portugal (ID 56648)
TBA (ID: SPS07_4)
Stefania Nannoni, Italy
Main aims:
1) Provide example of successful careers in Neurology boosted by EAN opportunities
2) Give the opportunity to RRFS member to ask questions to their colleagues who achieved
great results and managed to combine both clinical and research activities abroad.
3) Discuss the challenges that clinician-scientists have to face in the evolving landscape of
Neurology in Europe and how to bring back to their home countries the skills acquired.
4) Increase the awareness on the EAN fellowships as a successful career boosting scheme
For the 6th EAN congress, we are planning to organize a special session dedicated to the successful
stories of RRFS members who took advantage of EAN fellowships to unleash their potential and achieve
great results in the field of Neurology. The format of this special session is an interview in which
speakers will describe the impact of EAN fellowship in shaping their careers and then an open
discussion in which the participants can ask questions to the speakers. To promote this special session
as well as the call for EAN fellowships, the selected speakers will produce a small video of 3 min that
will serve as a trailer for both and will be uploaded on the EAN website.
(ID: SPS08) History of Neuroscience
Monday, 25 May 2020
8:00:00 AM - 9:30:00 AM
Room Budapest
Chairpersons: Danielle Seilhean, Paris France
Gilles de la Tourette: how he defined Tourette Syndrome
Olivier Walusinski, France
History of neuropathology in Salpetriere : contribution from French and foreign neurologists Danielle Seilhean, Paris France
From Gall to Broca; localisation in neurology
Peter Köhler, Herleen, The Netherlands
(ID: SPS09) Relevance of SEX DIFFERENCES in neurological disorders
Monday, 25 May 2020
8:00:00 AM - 9:30:00 AM
Room Seville
Chairpersons: Maria Teresa Ferretti, Zurich, Switzerland (ID: 94868) Elena Moro, Grenoble, France (ID: 51361)
Sex differences and human brain: overview and update (ID: SPS09_1)
Maria Teresa Ferretti, Zurich, Switzerland (ID: 94868)
Sex differences in stroke (ID: SPS09_2)
Anne Hege Aamodt, Oslo, Norway (ID: 50157)
Sex differences in neurodegenerative disorders (ID: SPS09_3)
Gennarina Arabia, Cosenza, Italy (ID: 63466)
Scientific/Educational Content:
A mounting body of evidence indicates that the male and female brains are affected by and respond
differently to a variety of neurological diseases. Whether this is due to biological (sex) or
socioeconomic reasons (gender) is still debated. This symposium will provide an overview of the issue,
by first introducing the concept of sex (biological makeup) and gender (socioeconomic construct), and
then offering examples from key neurological disease areas in the field of neurology. The symposium
will cover clinical aspects related to risk factors, progression and response to treatment in Stroke,
Alzheimer’s disease, and Parkinson’s disease in men and women, with particular attention to hormonal
interactions. These differences are of great interest for designing trials, improving prediction,
prevention and treatment approaches of neurological diseases.
(ID: SpS10) EAN/AFAN: Stroke management – What Africa can tell us
Tuesday, 26 May 2020
8:30:00 AM - 10:00:00 AM
Room Berlin
Chairpersons: Erich Schmutzhard, Innsbruck, Austria (ID: 7155)
Jean-Michel Vallat, Limoges, France (ID: 6574)
Thrombolysis and thrombectomy in North Africa: Challenges and Moroccan experience (ID:
SPS10_1)
Faouzi Belahsen, Fès, Morocco (ID: 93727)
Adapting stroke guidelines to African needs (ID: SPS10_2)
José M. Ferro, Lisbon, Portugal (ID: 19435)
Rehabilitation in resource-poor settings: does it work in Africa? (ID: SPS10_3)
Foad Abd-Allah, Cairo, Egypt (ID: 96105)
Scientific/Educational Content:
Stroke is a major public health concern worldwide. In low-middle income countries, especially in Africa,
nowadays, the management of acute strokes is often poor for several evident reasons; so, the
application of evidence-based acute stroke care interventions for optimal patient outcomes in such
countries seems quite often but not everywhere, still inadequate. It appears that guidelines which are
recommended in the Western world have to be adapted to this context. In a few countries like in
Maghreb, Ghana, Nigeria, South Africa and a few others, scarce studies indicate emerging evidence of
the availability of stroke unit care in hospital settings. So, at this time it seems interesting to discuss
and share the various experiences of neurologists from the African continent who take care of stroke
patients at the acute stage. It also must be stressed that rehabilitation is always and everywhere very
useful to take in charge, as soon as possible, such patients in adapted structures.
(ID: SPS12) European Brain Council: Severe patients in neurology and psychiatry: Detecting
- Managing – Refining
Sunday, 24 May 2020
8:00:00 AM - 9:30:00 AM
Room Seville
Chairpersons: Joke Jaarsma, Treasurer, European Brain Council
Frédéric Destrebecq, Executive Director, European Brain Council
Introduction
Joke Jaarsma
The Perspective of Neurology David B. Vodusek
Similarities in Psychiatry
Philip Gorwood
An integrated approach for managing severe patients living with brain disorders
Bruno Dubois
Open discussion
Frédéric Destrebecq
Wrap-up
Joke Jaarsma
Scientific/Educational Content: A wide range of commonalities exist in the domains of neurology and psychiatry as regards to the management of patients living with severe neurological or mental conditions. Such diseases greatly impact the lives of those affected. The aim of this session is to look into developing appropriate solutions and strategies that benefit patients in neurology and psychiatry. For that purpose, the session will bring together different perspectives on common aspects and challenges related to diagnosis and management as well as refinement of treatments and long-term specialist care of severely affected patients in neurology and psychiatry.